BullFrog AI Holdings, Inc. (BFRG)
D
Pipeline Grade
Financial Position (from SEC Filings)
$5.2M
Cash & Equivalents
$1.7M
Quarterly Burn Rate
9 mo
Est. Cash Runway
$13M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-08-01 | Phase2 Readout | — |
Active Clinical Trials (3)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT04433572 | Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee | PHASE3 | Recruiting | 250 |
| NCT04862468 | Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Acute F... | PHASE2 | Recruiting | 80 |
| NCT04858776 | Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Subacut... | PHASE2 | Active Not Recruiting | 60 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.